Muscarinic cholinoreceptors (M1-, M2-, M3- and M4-type) modulate the acetylcholine secretion in the frog neuromuscular junction

•M1-M5 muscarinic receptor subtypes were detected in the frog neuromuscular junction.•Electrophysiological studies have demonstrated the functioning of M1-M4 subtypes.•The depressing action of muscarine is mediated via M3 receptor activation. Muscarinic cholinoreceptors regulate the neurosecretion p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neuroscience letters 2017-05, Vol.649, p.62-69
Hauptverfasser: Tsentsevitsky, Andrei N., Kovyazina, Irina V., Nurullin, Leniz F., Nikolsky, Eugeny E.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•M1-M5 muscarinic receptor subtypes were detected in the frog neuromuscular junction.•Electrophysiological studies have demonstrated the functioning of M1-M4 subtypes.•The depressing action of muscarine is mediated via M3 receptor activation. Muscarinic cholinoreceptors regulate the neurosecretion process in vertebrate neuromuscular junctions. The diversity of muscarinic effects on acetylcholine (ACh) secretion may be attributed to the different muscarinic subtypes involved in this process. In the present study, the location of five muscarinic receptor subtypes (M1, M2, M3, M4 and M5) on the motor nerve terminals of frog cutaneous pectoris muscle was shown using specific polyclonal antibodies. The modulatory roles of these receptors were investigated via assessment of the effects of muscarine and specific muscarinic antagonists on the quantal content of endplate currents (EPCs) and the time course of secretion, which was estimated from the distribution of “real” synaptic delays of EPCs recorded in a low Ca2+/high Mg2+ solution. The agonist muscarine decreased the EPC quantal content and synchronized the release process. The depressing action of muscarine on the EPC quantal content was abolished only by pretreatment of the preparation with the M3 blockers 4-DAMP (1,1-Dimethyl-4-diphenylacetoxypiperidinium iodide) and J 104129 fumarate ((αR)-α-Cyclopentyl-α-hydroxy-N-[1-(4-methyl-3-pentenyl)-4-piperidinyl]benzeneacetamide fumarate). Moreover, antagonists of the M1, M2, M3 and M4 receptors per se diminished the intensity of secretion, which suggests a putative up-regulation of the release by endogenous ACh.
ISSN:0304-3940
1872-7972
DOI:10.1016/j.neulet.2017.04.015